ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESF31

Engineering a Multi-Therapeutic, 3D-Printed Scaffold for Local Immunoprotection and Favorable Engraftment of Pancreatic Islets for Treatment of Type 1 Diabetes

Completed
Institution
University of Florida, FL
Principal investigator
Taylor Rose Lansberry
Funding
$44K
Duration
2024–2026
Open portfolio

Moonbase score

Still being scored

Abstract

Project Summary/Abstract Type 1 diabetes mellitus is an autoimmune disorder in which the patient’s pancreatic islets are destroyed by their own immune system, leaving them unable to produce insulin to manage their blood glucose levels. Currently, this disease affects about 1.6 million people in the United States and roughly 180 new patients are diagnosed each day. Clinical islet transplantation is a potential solution that involves injecting donor islets into the patient’s liver to secrete insulin and regain blood glucose control. A challenge of this therapy, however, is decreased islet viability due to mechanical stress and adverse inflammation at the infusion site. The utilization of islet encapsulation or islet-loaded porous scaffolds can provide a means to protect islets from these stresses; however, encapsulation can result in insufficient engraftment and incomplete immunosuppression, while traditional scaffold fabrication methods generate inconsistent pores and rough surfaces that can lead to unfavorable and unpredictable host responses to the implant. To address these challenges, this proposal seeks to develop a multi-functional biomaterial scaffold that improves the vascularization, engraftment, and immunoprotection of transplanted pancreatic islets for the treatment of Type 1 diabetes mellitus. In Aim 1, we will alter scaffold porosity and rung thickness to identify the specific geometric features that will result in robust host engraftment with minimal fibrosis. For Aim 2, we will incorporate depots of synergistic immunosuppressants into the 3D-printed scaffold material for controlled local drug delivery. We will characterize the kinetic release curves of the drug eluting scaffold in vitro and optimize the drug loading parameters necessary for sufficient local immune protection. Islet-loaded, therapeutic scaffolds should provide local drug release resulting in the suppression of adverse immune reactions in an allograft rat transplant model, preventing rejection of the cell cargo. Broadly, results from this work will provide a better understanding of the roles that scaffold geometry and local therapeutic release play in cell-based therapies, while improving experimental outcomes in islet transplantation.

LOADING MOONBASE SCORE

F31NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESFellowships in Diabetes Endocrinology and Metabolic Diseases [DDK-E]pancreaticdiabetes mellitusencapsulationisletengraftmentblood glucoseisletsscaffold

Questions for University of Florida

Answered by the team behind this research.

Same institution, same topic, scored first.